Research reveals racial and ethnic disparities in the benefits of newer type 2 diabetes drugs

New research analyzing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations.

Tralokinumab Controls Moderate-to-Severe AD Over the Long Term

Tralokinumab (Adbry) was approved by the FDA in December 2021 for adult patients with moderate-to-severe atopic dermatitis based on data from three of the ECZTRA

November 28, 2023

This AI chat bot was trained on drag queens, and she wants to help protect your sexual health

A few months ago, a young Black gay patient in a southern state tapped out a message on his phone that he might not have

July 2, 2024

Opinion | The New Postpartum Depression Pill Is Not a Panacea

Blanc is a psychiatry professor and biobehavioral scientist. Following the FDA approval of the drug zuranolone (Zurzuvae) for treating postpartum depression (PPD), I analyzed some

August 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.